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Abstract: Vast numbers of studies and developments in the nanotechnology area have been 
conducted and many nanomaterials have been utilized to detect cancers at early stages. 
Nanomaterials have unique physical, optical and electrical properties that have proven to be 
very useful in sensing. Quantum dots, gold nanoparticles, magnetic nanoparticles, carbon 
nanotubes, gold nanowires and many other materials have been developed over the years, 
alongside the discovery of a wide range of biomarkers to lower the detection limit of cancer 
biomarkers. Proteins, antibody fragments, DNA fragments, and RNA fragments are the base 
of cancer biomarkers and have been used as targets in cancer detection and monitoring. It is 
highly anticipated that in the near future, we might be able to detect cancer at a very early 
stage, providing a much higher chance of treatment. 
Keywords:  cancer biomarkers; gold nanoparticles; quantum dots; carbon nanotubes; 
nanowires; microcantilevers 
 
1. Introduction  
Cancer diagnosis and treatment are of great interest due to the widespread occurrence of the 
diseases, high death rate, and recurrence after treatment. According to the National Vital Statistics 
Reports, from 2002 to 2006 the rate of incidence (per 100,000 persons) of cancer in White people  
was 470.6, in Black people 493.6, in Asians 311.1, and Hispanics 350.6, indicating that cancer is  
wide- spread among all races. Lung cancer, breast cancer and prostate cancer were the three leading 
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causes of death in the US, claiming over 227,900 lives in 2007 alone, according to the National Cancer 
Institute. Cancer is also greatly feared due to recurrences, as although treatable, tumors can return after 
a period of time, even after chemotherapy, surgery, or radiotherapy.  
Survival of a cancer patient depends heavily on early detection and thus developing technologies 
applicable for sensitive and specific methods to detect cancer is an inevitable task for cancer 
researchers. Existing cancer screening methods include: (1) the Papanicolau test for women to detect 
cervical cancer and mammography to detect breast cancer, (2) prostate-specific antigen (PSA) level 
detection in blood sample for men to detect prostate cancer, (3) occult blood detection for colon 
cancer, and (4) endoscopy, CT scans, X-ray, ultrasound imaging and MRI for various cancer detection. 
These traditional diagnostic methods however are not very powerful methods when it comes to cancer 
detection at very early stages. As well, some of the screening methods are quite costly and not 
available for many people. Therefore, the development of technology that is specific and reliable for 
detecting cancers at early stages and is easily accessible so that it can function as the first-line guidance 
is of utter importance. 
Biomarkers and nanotechnology, two mainstream fields in development of powerful diagnostic 
methods, are being extensively studied these days. This review will cover developments in cancer 
diagnosis methods using biomarkers and nanotechnology with an emphasis on the studies focusing 
largely on nanomaterials conducted in the past three years. 
2. Biomarkers 
A biomarker is an indicator of a biological state of disease. It is characteristic of a specific state and 
therefore can be used as a marker for a target disease. These biomarkers can be used to study cellular 
processes, and monitor or recognize disruption or alterations in the cellular processes of cancer cells. 
These results could provide us with information on the underlying mechanism of the initiation of a 
disease, the process of aggravation, and ultimately provide a method to diagnose and treat the disease 
with appropriate measures at desired time.  
A biomarker can be a protein, a fragment of a protein, DNA, or RNA-based. Biomarkers, 
specifically cancer biomarkers, are an indication of cancer and by detecting them the existence of that 
specific cancer can be verified. Alongside the development of proteomic technologies, many protein 
biomarkers have been discovered for many types of cancer. As well, with DNA methylation analysis 
researchers have also been able to discover DNA biomarkers for some of the widely spread cancers. 
Some of the biomarkers that are currently in use are listed below (Table 1).  
Biomarkers in relation with nanotechnology and biosensors have opened up a new era of early 
cancer diagnosis and precise drug delivery. Therefore thorough reviews on biomarkers have been 
written due to their high importance [26-29].  Sensors 2010, 10                  
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Table 1. Current cancer biomarkers in use. 
Cancer Markers  Characteristics 
Typical 
Sample 
Prostate 
PSA 
(Prostate specific antigen), 
total and free 
High sensitivity in all stages; also elevated from 
some non-cancer causes 
Blood [1,2] 
PSMA 
(Prostate specific membrane 
antigen)  
Levels tend to increase with age  Blood [3] 
Breast 
CA 15-3, 27, 29 
(Cancer antigen 15-3, 27, 29) 
Elevated in benign breast conditions. Either CA 
15-3 or CA 27, 29 could be used as marker 
Blood [1] 
Estrogen receptors 
Overexpressed in hormone-dependent cancer 
Tissue [4] 
Progesterone receptors  Tissue [4] 
Her-2/neu 
Only 20~30% of patients are positive to Her-2 
oncogene that is present in multiple copies  
Tissue [1,5] 
Lung 
(non-small cell) 
CEA 
(Carcinoembryonic antigen ) 
Used in combination with NSA to increase 
specificity, used also for colon cancer detection 
Blood [6] 
Lung 
(small cell) 
NSE  
(Neuron-specific enolase) 
Better sensitivity towards specific types of lung 
caner 
Blood [6] 
Bladder  
NMP22  
(Matritech’s nuclear matrix 
protein),  
BTA  
(Bladder tumor antigen) 
NMP-22 assays tend to have greater sensitivity 
than BTA assays 
Urine [1,7] 
Pancreatic 
BTA   Composed of basement membrane complexes  Urine [1,7] 
CA 19-9  
(Carbohydrate antigen 19-9) 
Elevated also in inflammatory bowel disease, 
sometimes used as colorectal cancer biomarker 
Blood [1,8,9] 
Epithelial ovarian cancer  
( 90 % of all ovarian cancer ) 
CA 125  
(Cancer antigen 125) 
High sensitivity in advanced stage; also 
elevated with endometriosis, some other 
diseases and benign conditions 
Blood [1,10] 
Germ cell cancer of ovaries  
CA 72-4 
(Cancer antigen 72-4) 
No evidence that this biomarker is better than 
CA-125 but may be useful when used in 
combination 
Blood [11] 
AFP 
(Alpha-fetoprotein) 
Also elevated during pregnancy and liver 
cancer  
Blood [1,12] Sensors 2010, 10                  
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Table 1. Cont. 
Multiple myeloma and 
lymphomas 
B2M  
(Beta-2 microglobulin) 
Present in many other conditions, including prostate 
cancer and renal cell carcinoma. 
Blood [13] 
Monoclonal 
immunoglobulins 
Overproduction of an immunoglobulin or antibody, 
usually detected by protein electrophoresis 
Blood, 
urine [14] 
Metastatic melanoma 
S100B  Subunit of the S100 protein family  Serum [15] 
TA-90 
(Tumor-associated 
glycoprotein Antigen) 
Could be used to monitor patients with high risks of 
developing the disease 
Serum [16] 
Thyroid  Thyroglobulin  Principal iodoprotein of the thyroid gland 
Serum, 
tissue [17] 
Thyroid medullary 
carcinoma 
Calcitonin  Secreted mainly by parafollicular C cells 
Blood, 
serum [18] 
Testicular 
hCG  
(Human chorionic 
gonadotropin) 
May regulate vascular neoformation through vascular 
endothelial growth factor (VEGF) 
Serum 
[1,19] 
Waldenstrom’s 
macroglobulinemia 
(WM) 
Monoclonal immunoglobulin 
M 
The larger size and increased concentration of the 
monoclonal protein leads to serum hyperviscosity, the 
most distinguishing feature of WM 
Blood, 
urine [20] 
Lymphomas B2M   
Present in many other conditions, including prostate 
cancer and renal cell carcinoma 
Serum [21] 
Lung (non small cell), 
epithelial, colorectal, 
head and neck, 
pancreatic, or breast 
EGFR 
(Her-1) 
Binding of the protein to a ligand induces receptor 
dimerization and tyrosine autophosphorylation and 
leads to cell proliferation 
Tissue [1, 
22] 
Colorectal, lung, breast, 
pancreatic, and bladder 
CEA  
(Carcinoembryonic antigen ) 
Subtle posttranslational modifications might create 
differences between tumor CEA and normal CEA 
Serum 
[1,23,24] 
T-cell acute 
lymphoblastic leukemia 
(T-ALL) 
PTK7  
Membrane-bound surface protein of whole cells, and 
can be used to detect circulating tumor cells as targets 
Blood [25] 
3. Nanomaterials and Biomarkers 
Nanotechnology has been developing rapidly during the past few years and with this, properties of 
nanomaterials are being extensively studied and many attempts are made to fabricate appropriate 
nanomaterials. Due to their unique optical, magnetic, mechanical, chemical and physical properties 
that are not shown at the bulk scale, nanomaterials have been used for more sensitive and precise Sensors 2010, 10                  
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biomarker detection. Nanomaterials that have been applied to sensing cancer biomarkers vary from 
gold nanoparticles, quantum dots, magnetic nanoparticles, carbon nanotubes and nanowires [30-32].  
3.1. Gold Nanoparticles 
Gold nanoparticles (GNPs) have been in the bio-imaging spotlight due to their special optical 
properties. GNPs with strong surface-plasmon-enhanced absorption and scattering have allowed them 
to emerge as powerful imaging labels and contrast agents. They have better absorption and scattering 
bands than conventional organic dyes, the cross section of the bands going up to four to five orders of 
magnitude higher [33]. Furthermore, GNPs have been proven to be more biocompatible, less cytotoxic, 
and resistant to photobleaching according to human cell experiments [34]. Another unique property of 
the GNPs is the size-tunable optical properties. According to their size and shape, GNPs can absorb 
and scatter light from the visible to near-infrared (NIR) region [35].  
GNPs have been extensively studied, especially in the medical area, and have been used as 
colorimetric biosensors [36-38], cancer imaging [39,40], cancer therapy [41-43], and drug delivery [44]. 
They have been found to amplify the efficiency of Raman scattering and thus have been proposed as a 
novel tag. A class of nontoxic nanoparticles for in vivo tumor targeting based on pegylated colloidal 
gold (colloidal gold coated with a protective layer of polyethylene glycol) and surface-enhanced 
Raman scattering (SERS) has been reported [45]. These gold nanoparticles have been encoded with 
Raman reporters and conjugated with ScFv antibody for in vitro and in vivo tumor targeting, 
recognizing the epidermal growth factor receptor (EGFR) which is a popular biomarker used in cancer 
targeting (Figure 1).  
Figure 1. Cancer cell targeting and spectroscopic detection using antibody-conjugated 
SERS nanoparticles. (a) Modified gold nanoparticle with Raman reporter and targeting 
molecule. (b) Schematic illustration of the nanoparticles targeting the cancer cells. 
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These SERS GNPs with ScFv antibody to target EGFR were more than 200 times brighter than NIR 
emitting quantum dots, and allowed spectroscopic detection of small tumors (0.03 cm
3) at penetration 
depth of 1–2 cm.  
For GNPs as stable and versatile molecular imaging agents, a complementary oligonucleotide-based 
approach has been proposed. A 5’-thiol-modified and 3’-NH2-modified oligonucleotide was coated 
onto the nanoparticles and subsequently conjugated with anti-EGFR proteins through DNA-DNA 
hybridization. Through this study, gold nanoparticles have proven to be effective reflectance contrast 
agents for molecular imaging. As well, by hybridizing oligonucleotides with reporting molecule, the 
modified GNPs could also be used as a multifunctional contrast agent and be imaged with fluorescent 
confocal microscopy in parallel (Figure 2). These modified GNPs have been proven to be superior to 
contrast agents where the protein was adsorbed directly, in terms of size and stability [46].  
Figure 2. Functionalization of GNPs through hybridization oligonucleotides. 
 
Plasmon resonance coupling between closely spaced metal nanoparticles have been applied in in 
vitro bioanalytical assays. However a recent study has been conducted where plasmon resonance 
coupling was used for in vivo molecular imaging of carcinogenesis. Anti-EGFR antibodies were 
conjugated to gold nanoparticles and these nanoparticles were used to obtain information on the   
over-expression and nanoscale spatial relationship of EGFRs in cell membranes. EGFR-mediated 
aggregation of GNPs results in color shift and a contrast ratio much superior than those with 
fluorescent dyes when normal and precancerous epithelium were imaged in vivo [47]. 
Dynamic light scattering (DLS) analysis can also be used for biomarker sensing. A combination of 
GNPs and gold nanorods conjugated with anti-Prostate Specific Antigen (PSA) antibody was used as a 
one-step homogeneous immunoassay for cancer biomarker detection. Through DLS analysis, the 
relative ratio of nanoparticle aggregate versus nonaggregated nanoparticles can be measured 
quantitatively. The relative ratio should therefore increase according to the amount of antigen in 
sample solution and this relationship is the basis of the homogeneous immunoassay (Figure 3). This 
study was conducted in solution, contrary to the traditional plate-based immunoassay, therefore Sensors 2010, 10                  
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allowing better mixing between antigen and antibody. This enables biomarker detection at very low 
concentrations [48]. 
Figure 3. Aggregation of GNPs and gold nanorods in the presence of PSA, leading to DLS 
analysis for the immunoassay. 
 
 
Gold nanoparticles are used as molecular imaging agents, but GNP film electrodes have also been 
proven to be useful in detecting cancer biomarker proteins. By applying multilabeled detection 
antibody-magnetic bead bioconjugates, an ultrasensitive electrochemical immunosensor for cancer 
biomarker proteins has been designed. Magnetic beads have been conjugated with horse radish 
peroxide (HRP) and a secondary antibody, providing multiple enzyme labels for each PSA to be 
detected. On the surface of the GNP electrode, capture antibodies have been attached for PSA antigen 
binding. By applying voltage and H2O2, a sensitive immunosensor was realized (Figure 4). The authors 
claimed the immunosensor was better than a previously reported carbon nanotube (CNT) forest 
immunosensor with multiple labels on the CNTs [49]. 
Figure 4. GNP electrode and magnetic beads functionalized with multiple enzyme labels. 
 
In addition to spherical gold nanoparticles, gold nanoshells [50,51]
 and gold nanorods [52] have 
been applied to biomarker detection. They have been of particular interest because they can absorb and Sensors 2010, 10                  
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emit light at NIR region providing deep tissue penetration which is very important in in vivo imaging. 
As well, these nanoparticles have been very useful as a photothermal cancer treatment agent.  
3.2. Quantum Dots 
Quantum dots (QDs) are semiconducting, light-emitting nanocrystals that have emerged as a 
powerful molecular imaging agent since their discovery. QDs are an exciting material to work with 
due to their unique optical properties compared to traditional organic fluorescent labels [53]. Organic 
fluorescent dyes have several drawbacks that have limited their usefulness as molecular imaging tags. 
Their low photobleaching threshold and broad absorption/emission peak width have hindered their use 
in long term imaging and multiplexing (detecting multiple labels simultaneously) [54]. QDs have 
properties that overcome these limitations of the organic fluorescent dyes including high resistance to 
photobleaching [55], broad-band absorption with narrow emission bands ranging from UV to   
NIR [56,57], and size tunable emission bands [58,59]. These exceptional optical properties of QDs 
have made them an exciting field of study for many researchers in search of molecular imaging tools 
for better cancer diagnosis.  
Figure 5. Schematic design of the multifunctional nanoparticle. QDs conjugated with an 
aptamer targets the cancer biomarker. By releasing the drug from the conjugate, both the 
QD and drug recovers its fluorescent property. 
 
 
A multifunctional nanoparticle with biomolecules conjugated to QDs has been used in cancer 
targeting and drug delivery [60]. A10 RNA, aptamer that recognizes prostate specific membrane 
antigen (PSMA), was conjugated to the QD to target cancer cells [61]. Doxorubicin (DOX), a well 
known anthracycline drug with fluorescent properties, was intercalated in the conjugate. This 
conjugate offers an exciting method of imaging cancer cells. The intercalated DOX within A10 RNA 
conjugated to the QD quenches the fluorescence of both DOX and QD. When the QD-aptamer (DOX) 
conjugate finds the target cancer biomarker, it is taken into the cancerous cell through endocytosis. 
When DOX is released from the conjugate, both of them recover their fluorescent properties and thus 
can be imaged. With this design, the multifunctional nanoparticle can be fabricated so that cancer Sensors 2010, 10                  
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biomarkers can be detected precisely and the drug is delivered within the cancer cell, giving high 
specificity (Figure 5).  
QDs can be used as signal amplifying agents in ultrasensitive cancer biomarker detection [62]. A 
recent study has been conducted with QD functionalized nanoparticles in immunoassays, targeting 
alpha-fetoproteins (AFPs) [63]. CdTe QDs have been coated on SiO2 particles and through anodic 
stripping voltammograms, the Si/QD/antibody showed increased oxidation current of Cd
2+ proving its 
signal amplifying ability. Increased amount of QDs per biomarker make the detection more sensitive, 
thus enabling detection even at low concentration (Figure 6).  
Figure 6. QD functionalized Si nanoparticles for signal amplification. 
 
 
Magnetic particles have also been functionalized with QDs for cancer targeting, separation and 
imaging [64]. A high fluorescent multi-labeling could be achieved with this conjugation, providing 
both magnetic manipulation and multicolor fluorescent images. By immobilizing anti-epithelial cell 
adhesion molecule (EpCAM) antibody, this conjugate targeted tumor cells circulating tumor cells [65]. 
The conjugation of magnetic particle, QDs, and antibody is however very complex requiring multiple 
steps. Therefore many studies are conducted to find out easier methods to fabricate them.  
QDs have also been integrated into nano-bio-chips (NBCs) for detecting multiple cancer   
biomarkers [66]. Recently, an exciting new technique has been developed using QDs in nano-bio-chips. 
QD-labeled antibodies were used for multiple-color-fluorescence transduction signaling NBCs in 
combination with antigen capture by a microporous agarose bead array held in microfluidics [67]. 
Cancer biomarkers of interest were carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), 
and Her-2/neu in serum and saliva samples. This type of miniaturized chip proved to be superior to 
traditional enzyme-linked immunosorbent assay (ELISA), reducing the detection limit by nearly two 
orders of magnitude.  
3.3. Other Nanoparticles 
Other various nanoparticles have also been investigated for cancer biomarker detection. Metal 
nanoparticles, magnetic nanoparticles, silica nanoparticles and many other have caught the attention of 
researchers due to their unique properties.  Sensors 2010, 10                  
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Encapsulated phase change nanoparticles have been investigated as a multiplexed highly sensitive 
cancer biomarker detection agent [68]. Phase change nanoparticles have unique thermophysical 
properties. Phase change materials (PCM) can absorb thermal energy without temperature rise during 
the melting process. Heat transfer from surrounding environment to the core of PCM takes time in 
practice and that broadens the melting peak at temperature scan of a constant rate. By silica 
encapsulation, changes in composition of the metal within can be prevented, thus providing thermal 
barcodes with melting peaks broadening according to the concentration of the target molecule.  
Silica nanoparticles doped with fluorescence resonance energy transfer (FRET) dyes have been 
investigated as simultaneous and multiplexed detection [69]. Recently, a study has been conducted 
using these FRET nanoparticles to monitor cancer cells [70]. By modifying the nanoparticles with 
aptamers targeting T-cell leukemia and B-cell lymphoma and by changing doping ratio of the dyes 
trapped inside the silica shell, a variety of fluorescent emission spectra could be obtained with a single 
excitation wavelength.  
Figure 7. Mechanism of decrease in relaxation time due to magnetic   
nanoparticle aggregation. 
 
 
Magnetic nanoparticles have been widely used in cancer cell imaging. By using the principle of 
decrease in transverse relaxation time due to aggregation of magnetic nanoparticles in presence of 
target molecules, concentration of cancer biomarkers could be measured [71]. This device allowed in 
vivo, local environment monitoring for cancer biomarkers and could be left implanted after tumor 
surgery. This exciting new method is expected to be a convenient method for continuous monitoring 
since biopsies do not have to be performed for each screening. A similar approached has also been 
used in the past to develop a biosensor to detect cancer biomarkers in turbid samples (blood, urine, and 
sputum) [72]. When magnetic particles aggregate through affinity ligands to the molecular target, a 
decrease in the bulk spin-spin relaxation time of surrounding water molecules occurs. This could be 
used as a chip-based nuclear magnetic resonance (NMR) system, and with miniaturization and 
multiplexing, detection of various biomarkers within a small sample volume could be achieved (Figure 7).  Sensors 2010, 10                  
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3.4. Carbon Nanotubes 
After the discovery of fullerene, carbon nanotubes (CNTs) have been re-discovered in 1991 by 
Iijima [73]. Since then, CNTs have been constantly in the spotlight and have emerged as a powerful 
sensing vehicle due to their exciting properties. The conductance of the semiconducting CNT changes 
when biomolecules are adsorbed on the walls, causing changes in local electrostatic environment. 
Many exceptional properties of CNTs allow them to be applied for sensing biomarkers 
electrochemically; CNTs provide high surface-to-volume ratios, mediate fast electron-transfer and can 
be functionalized with almost any desired chemical species. It is also of great advantage to use carbon 
nanotubes because label-free detection of cancer biomarkers is possible. Label-free detection is based 
on molecular recognition events, requiring fewer steps in sample preparation compared to labeled-
detection. Of course not only electrochemical biosensing is possible with CNTs, but also incorporating 
label molecules for imaging is also possible. Numerous studies on CNT-based biosensors have been 
conducted since the development of CNT electrodes for low potential detection of NADH [74-79]. 
Current developments in CNT-based cancer detection focus on a more precise and sensitive 
detection of the cancer biomarkers. A multifunctional dendrimer-modified multiwalled carbon 
nanotube (MWNT) has been recently developed. The dendrimers, poly(amidoamine), are highly 
branched, monodispersed macromolecules with well-defined architecture making them an ideal 
platform to covalently link molecules of interest (Figure 8). This approach allows single-step 
modification of the CNTs for cancer cell targeting and imaging [80].  
Figure 8. MWNT functionalized with fluorescein isothiocyanate (FI) and folic acid (FA) 
modified amine-terminated dendrimers. FA is for targeting cancer cells that over-expresses 
FA receptors and FI dye for imaging. 
 
Single-wall carbon nanotubes (SWNT) with [Ru-(bpy)3]
2+-doped silica nanoparticles have been 
studied as an electrochemiluminescent immunosensor for PSA detection (Figure 9). The doped silica 
nanoparticle provides significant electrochemiluminescent signal amplification by trapping thousands 
of [Ru-(bpy)3]
2+ (RuBPY) and can be detected with a much simpler measurement systems than the 
commercial bead-based electrochemiluminescence (ECL) assays. Thus, an ultrasensitive amperometric 
immunosensor for PSA detection has been designed based on CNTs [81]. 
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Figure 9. SWNT forest with ECL nanoparticles as sandwich immunoassay for PSA detection. 
 
A multilayered enzyme-coated carbon nanotube design has been studied as an ultrasensitive 
chemiluminescence immunoassay (CLIA) for detecting AFP in human serum samples. Horse radish 
peroxide (HRP) was absorbed into MWNTs, allowing maximized ratio of HRP/antibodies for 
sensitivity enhancement. After separating the MWNT-AFP by applying magnetic beads with 
antibodies, bromophenol blue (BPB) and H2O2 was added to the separated solution. The 
chemiluminescence reaction was triggered by injecting luminol into the solution (Figure 10). This 
system proved to have a detection limit that was two orders of magnitude lower than standard ELISA 
method [82]. 
Figure 10. Multilayered enzyme-coated CNTs as labels for chemiluminescence immunoassay. 
 
 
As mentioned above, by using CNTs label-free detection of biomolecules is possible. As well, due 
to their advantages many studies have been conducted on the development of CNT based biosensors. 
CNT field effect transistor (FET) based biosensors are especially of great interest [83]. CNTs form the 
conducting channel in a transistor configuration and interact with introduced analytes. Analytes 
interact with CNTs where 1) charge transfer may occur from analyte molecules to the CNTs or 2) the 
analytes can act as scattering potential across the CNTs. A relationship between the concentration of Sensors 2010, 10                  
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the analyte and conductance or potential can be monitored and biosensing can be done based on this 
system. A real-time detection of PSA-ACT complex with CNT-FET has been developed and by 
providing sufficient space between each antibody on the CNT, the sensitivity of the system was 
maximized (Figure 11). This spacing is a crucial element of sensing biomarkers in a buffer solution 
since the target is required to be in a distance within the Debye length to give a large gating effect. 
Using 1-pyrene butanoic acid succinimidyl ester (PASE) as a linker and 1-pyrenebutanol (PB) as a 
spacer at a specific linker-to-spacer ratio on SWNTs, conductance of CNT-FET could be largely 
enhanced [84].  
Figure 11. Set up of CNT-FET with a linker and a spacer for the maximized sensitivity. 
 
 
Another interesting study has been done using CNT-FET for biomarker detection in breath   
samples [85]. A sensor array of FETs based on random networks (RNs) of SWNTs for detection of 
lung cancer biomarkers from exhaled breath samples was designed, showing a clear discrimination 
between volatile organic compounds (VOCs) of healthy controls and patients with lung cancer. 
Conductance response of RN-CNT FETs to nonpolar biomarkers in gas phase was obtained by 
scattering of carriers and response of same devices to polar biomarkers was achieved from charge 
transfer from polar adsorbates [86]. Through principal components score plots, a significant difference 
was observed between healthy controls and cancer patients.  
3.5. Nanowires 
Various nanowires have also been applied to biomarker detection including silicon nanowires [86-89], 
In2O3 nanowires [77], gold nanowires [90,91], conducting polymer nanowires [92].  
Silicon nanowires (SiNW) are semiconducting nanowires with exceptional physical, optical, 
electronic properties, and excellent biocompatibility [93-96]. As well, since silicon is a well studied 
material, the surface of the nanowires can be modified with well-known methods. This advantage 
makes itself a promising platform for sensitive detection of biomarkers [97,98]. SiNWs modified with 
peptide nucleic acids (PNAs) have been used to detect miRNAs that were extracted from Hela cells. 
This system was developed to detect RNA cancer biomarkers [99]. Resistance change was measured Sensors 2010, 10                  
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before and after the hybridization of the complimentary PNA and miRNA, and it was shown that this 
change correlates directly to the concentrations of the target miRNA (Figure 12). 
Figure 12. Target miRNA detection via PNA functionalized SiNW. 
 
 
Vascular endothelial growth factor (VEGF), yet another cancer biomarker, has been detected 
electrically with functionalized SiNWs. This system is also label-free biosensing with both n-type and 
p-type SiNWs functionalized with anti-VEGF aptamers with current change occurring according to 
molecular recognition [100]. In addition to silicon nanowires, voltammetric detection of cancer 
biomarkers using silica nanowires (SiO2-NWs) has also been studied. A lung cancer biomarker, 
interleukin-10 (IL-10) and osteopontin (OPN), has been detected using silica nanowires as templates, 
through electrochemical alkaline phosphatase (AP) assay (Figure 13).  
Figure 13. Detection of cancer biomarker through sandwich immunoassay using SiO2-NW. 
 
 
The streptavidin-coated AP enzyme was attached to the biotinylated detector antibody which then 
was used to hydrolyze p-nitrophenyl phosphate (pNPP) substrate to produce p-nitrophenol (pNP). The 
electro-oxidation of pNP occurrence was measured and the anodic peak current was shown to have a 
linear relationship with the concentration of the cancer biomarkers [101]. 
SiO2-NWs with functionalized QDs on a patterned gold substrate have been studied as an optical 
sensor for cancer biomarkers (Figure 14). The fluorescent intensity was ten-fold than a silica substrate 
case, and the signal was specified to IL-10 [102]. Metal-decorated SiO2-NWs have been studied as an 
active SERS substrate for cancer biomarker detection [103] with specificity towards IL-10.  Sensors 2010, 10                  
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Figure 14. Optical sensing of IL-10 using functionalized SiO2-NW and QD labels on a 
patterned Au substrate. 
 
Functionalized gold nanowires enhance sensitivity and selectivity for cancer biomarkers detection 
by providing high surface-to-volume ratio. Electrochemical detection based on alkaline phosphatase 
enzyme reaction was also used with gold nanowires instead of silicon nanowires [104]. CK-7, a protein 
expressed in epithelial tissues and can be used as a biomarker to distinguish between different cancer 
cells, was detected by employing gold nanowires as a template for the enzyme immunoassay. Gold 
nanowires functionalized with PNA-nanowire have also been investigated as a potential cancer 
diagnostic system [105]. RNA-DNA hybridization events were detected using an electrocatalytic 
reporter system, and the cellular and clinical samples did not need any labeling or PCR amplification 
(Figure 15). As a variation of the nanowire electrodes, a nanostructured microelectrode (NME) system 
has been developed for mRNA samples of prostate cancer related genes. Palladium NME was 
constructed on a chip by electrodeposition, and modified with thiol-derivatized PNA probes for mRNA 
detection. The electrocatalytic signal was monitored for the hybridization events, and the current 
increase was observed in the presence of the complementary RNA [106]. 
Figure 15. RNA detection via PNA functionalized gold nanowire (AuNW). Solution 
contains two redox reporter groups; Ru(NH3)6
3+ and Fe(CN)6
3–. Ru(NH3)6
3+ is attracted by 
DNA at electrode surface and through negative potential sweep, Ru(III) is reduced and 
regenerated by Fe(III) oxidant for multiple turnovers. 
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Conducting polymer nanowires were synthesized for chemoresistive sensor device. Polypyrrole 
(Ppy) nanowires were used in this study and the surface was functionalized with cancer antigen   
CA 125 antibody (Figure 16). A single Ppy nanowire was integrated into a FET system, just like 
carbon nanotubes, and the measurements of changes in conductivity due to biomolecule recognition 
events were measured [107]. 
Figure 16. FET system with single Ppy nanowire as semiconducting channel to detect CA 125. 
 
3.6. Other Nanotechnology (Cantilever and Nanopore) 
Microfabricated cantilevers bend according to changes in the environment or changes on their 
surfaces, and this bending is in the nanometer-scale [108,109]. This nanometer-scale bending allows 
them to be in the category of nanotechnology even though its whole size is in the micrometer-scale and 
can be used as a component of biosensors. Microcantilevers have been applied to pH detection [110,111], 
protein detection [112-117], DNA/RNA-DNA/RNA hybridization events [118-124]. A thorough 
review on microcantilevers applied in biosensors has been published which discloses that 
microcantilevers are a unique tool for detecting biomolecules of interest [125]. 
Recently many developments have been made on microcantilever based biosensors in the area of 
cancer biomarker detection. Surface stress was measured for antigen-antibody binding, specifically 
PSA and its antibody [126]. PSA antibodies were conjugated onto the cantilever with specific linkers 
and in order to reduce background signals, the surface was passivated with PEG-silane. Depending 
upon the concentration of the antigen, surface stress increased linearly thus providing a system for 
cancer biomarker detection based on mechanical deflection (Figure 17). 
Figure 17. Microcantilever based cancer biomarker detection. Deflection of the cantilever 
due to antibody-antigen binding is detected by monitoring reflected laser beam. 
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Resonant microcantilevers are also used for sensing biomarkers. Mass change results in a shift in 
frequency and by observing the shift that originated from the antibody-antigen reaction, an effective 
biosensor can be designed. A cancer biomarker, CEA, was detected through this method and the 
microcantilever was coated with a piezoelectric film. In this system, frequency shift occurs by 
molecular interaction and showed decreasing shift proportional to the target concentration [127]. By 
fabricating the system with rotating-mode resonant micro-cantilevers, a different type of cancer 
biomarker, AFP, could be significantly lowered thus providing a potential method of detecting cancer 
at very early stages [128]. Further development has been made which can be used in undiluted serum 
sample for cancer detection. Because the resonant frequency was altered by the degree of the 
molecular interaction, the system could be used as a biosensor for actual human samples [129]. 
A different approach in detecting cancer cells is measuring the cell stiffness. The cell stiffness here 
is itself the biomarker thus making it possible to differentiate cancer cells from normal healthy cells. 
Atomic force microscopy (AFM) is a widely used instrument to measure infinitesimal forces and in 
this biosensing system, the elasticity of the cells is measured (Figure 18). Histograms of the measured 
elasticity showed significant difference between cancer cells and normal cells, with cancer cells having 
a stiffer elasticity and a narrower distribution [130]. 
Figure 18. Healthy cell and cancer cell differs in stiffness. 
 
 
Nanopores, including synthetic, artificial, and protein-based, have been of great interest to many 
researchers for detecting biomolecules. Various studies have been conducted on nanopores for sensing 
biomolecules including DNA [131-133], proteins [134,135], ions [136,137], and drug molecules [138]. 
Nanopore membranes functionalized with antibodies was used to detect hepsin and PSA (Figure 19). 
Electrochemical impedance spectroscopy was used to monitor changes in ionic conductance before 
and after the antigen-antibody interaction. Results showed increased impedance after the specific 
interaction, and a linear relationship of change in impedance versus antigen concentration was 
recorded [139]. 
Figure 19. A Nanopore applied in antigen detection. The impedance change is monitored. 
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Methylated DNA can be used as cancer biomarkers for cancer diagnosis and these DNA strands can 
also be detected by using nanopores. Synthetic nanopores in Si3N4 membranes have been fabricated 
and the permeation of methylated DNA passing through the pore was measured. Electric field was 
used to force translocation of a single DNA across the membrane. The degree of methylation is 
detected by forcing one molecule to go through the pore at a time and measuring the voltage threshold 
for each DNA. By being able to discriminate methylation level, it will be possible to apply this system 
to cancer diagnosis [140]. 
As a type of synthetic nanopores, fabricated nanopipettes have also been studied and developed for 
sensing applications for DNAs [141-143], and ions [144], and proteins [145]. Currently, methods of 
label-free-detection of cancer biomarkers have also emerged. Binding of the target molecule on to the 
surface of the fabricated nanopipette alters the ionic current due to partial blocking or change in the 
surface charge [146]. This scheme provided a method of detecting VEGF and IL-10, which bound to 
the surface of the pipette through the capturing antibodies (Figure 20). 
Figure 20. Nanopipette detecting IL-10 or VEGF. 
 
4. Conclusions  
This review summarized recent developments in cancer detection methods with an emphasis on 
nanotechnology. Nanomaterials have unique features that are attractive, and can be applied to 
biosensing. The development of various nanomaterials and nanotechnology has enabled detection of 
cancer biomarkers with great precision and sensitivity that could not be achieved before. The low 
detection limit obtained by nanotechnology is expected to contribute immensely to the early detection 
and accurate prognosis of cancers. Since it is of huge importance to be able to diagnose cancer as early 
as possible, many studies are being conducted on developing sensing mechanisms that will push down 
the detection limit as far down as possible. As well, various new biomarkers can be discovered and 
verified with such sensitive tools. It is therefore highly anticipated that in the near future, 
nanotechnology shall help to detect cancer at an early stage and monitor the disease with much greater 
precision. It must be however noted that these new technologies must be validated critically before 
applying them for clinical diagnosis. Although detecting cancers at early stages is very attractive, 
factors such as probability of getting false positive/negative and impact of nanomaterials on human 
and environment should be fully understood. Sensors 2010, 10                  
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